文献速递技术与安全MR

B1不均匀性对动态增强MRI药代动力学建模的影响:一项仿真研究

Influence of B1-Inhomogeneity on Pharmacokinetic Modeling of Dynamic Contrast-Enhanced MRI: A Simulation Study.
PubMed 文献 · Korean J Radiol · 2017-05-19

该仿真研究在体模中估计B1不均匀性所致翻转角(FA)变化,并用蒙特卡洛模拟评估FA偏差对增强前R1、对比增强率、钆浓度及两室药代动力学参数(Ktrans、ve、vp)测量误差的影响。结果显示FA波动为-23%至5%,即使很小的B1不均匀性也可导致药代动力学参数显著测量误差,增强前R1计算对FA偏差的脆弱性是误算的重要原因。

要点

  • B1不均匀性引起FA波动范围-23%至5%(95%CI of % error)。
  • FA偏差所致Ktrans误差范围-43.1%至48.4%,ve误差-32.3%至48.6%,vp误差-43.2%至48.6%。
  • 增强前R1比对比增强率对FA误差更脆弱,是钆浓度误差的重要原因。

核心结论

  • 即使很小程度的B1不均匀性也可导致DCE-MRI药代动力学参数测量的显著误差,而增强前R1计算对FA偏差的脆弱性是误算的重要原因。

研究设计与样本

  • 仿真研究:先通过体模研究估计B1不均匀性所致FA变化,再进行蒙特卡洛模拟评估FA偏差所致增强前R1、对比增强率、钆浓度及两室药代动力学参数(Ktrans、ve、vp)的测量误差。

诊断标准与关键数值

  • FA的B1不均匀性所致波动范围:-23%至5%(95%CI of % error)。
  • 灰质中FA依赖的%误差95%CI:增强前R1为-16.7%至61.8%,对比增强率为-1.0%至0.3%,钆浓度为-14.2%至58.1%。
  • 血液中FA依赖的%误差95%CI:增强前R1为-16.7%至61.8%,对比增强率为-5.2%至1.3%,钆浓度为-14.1%至57.8%。
  • 药代动力学参数%误差范围:Ktrans为-43.1%至48.4%,ve为-32.3%至48.6%,vp为-43.2%至48.6%。
  • 举例:-10% FA误差导致增强前R1偏差23.6%、对比增强率偏差-0.4%、钆浓度偏差23.6%。

临床应用与阅片要点

  • 在模拟条件下,靶病灶FA误差3%且供血血管FA误差-10%时,药代动力学参数%误差分别为Ktrans -23.7%、ve -23.7%、vp -23.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To simulate the B1-inhomogeneity-induced variation of pharmacokinetic parameters on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

MATERIALS AND METHODS: B1-inhomogeneity-induced flip angle (FA) variation was estimated in a phantom study. Monte Carlo simulation was performed to assess the FA-deviation-induced measurement error of the pre-contrast R1, contrast-enhancement ratio, Gd-concentration, and two-compartment pharmacokinetic parameters (Ktrans, ve, and vp).

RESULTS: B1-inhomogeneity resulted in -23-5% fluctuations (95% confidence interval [CI] of % error) of FA. The 95% CIs of FA-dependent % errors in the gray matter and blood were as follows: -16.7-61.8% and -16.7-61.8% for the pre-contrast R1, -1.0-0.3% and -5.2-1.3% for the contrast-enhancement ratio, and -14.2-58.1% and -14.1-57.8% for the Gd-concentration, respectively. These resulted in -43.1-48.4% error for Ktrans, -32.3-48.6% error for the ve, and -43.2-48.6% error for vp. The pre-contrast R1 was more vulnerable to FA error than the contrast-enhancement ratio, and was therefore a significant cause of the Gd-concentration error. For example, a -10% FA error led to a 23.6% deviation in the pre-contrast R1, -0.4% in the contrast-enhancement ratio, and 23.6% in the Gd-concentration. In a simulated condition with a 3% FA error in a target lesion and a -10% FA error in a feeding vessel, the % errors of the pharmacokinetic parameters were -23.7% for Ktrans, -23.7% for ve, and -23.7% for vp.

CONCLUSION: Even a small degree of B1-inhomogeneity can cause a significant error in the measurement of pharmacokinetic parameters on DCE-MRI, while the vulnerability of the pre-contrast R1 calculations to FA deviations is a significant cause of the miscalculation.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Park B, Choi BS, Sung YS, et al. Influence of B1-Inhomogeneity on Pharmacokinetic Modeling of Dynamic Contrast-Enhanced MRI: A Simulation Study. Korean J Radiol. 2017. PMID: 28670153. doi:10.3348/kjr.2017.18.4.585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。